Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature
Ocular Oncology and Pathology · 2024 · 10 (3) · 154-161
DOI: 10.1159/000539434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 24.05.2024. Verfasst von Farzad Jamshidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The systemic HIF-2 alpha inhibitor, belzutifan, has been approved for use in patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors. This drug has also shown promise in controlling VHL retinal hemangioblastomas (RHs), but little work has been published on the use of the drug in this setting.
Methods
We conducted a retrospective review of patients with VHL-associated RHs followed by the retina service at our institution who were treated with systemic belzutifan. Patient age, gender, genotype, presence of systemic tumors, indication for the drug, initial dose, adjusted dose, side effects, and tumor response were recorded. We also conducted a literature search for all manuscripts describing the effect of belzutifan on VHL-associated ocular tumors.
Results
We identified 12 eyes of 7 patients with VHL-associated ocular tumors who were treated with belzutifan at our institution. Of these, 5 eyes of 3 patients had progressing ocular tumors when belzutifan was started. Of the 7 total patients, 2 were treated for renal cell carcinoma, 2 for CNS hemangioblastomas, 2 for RHs, and one for pancreatic neuroendocrine tumors. Initial dose was 120 mg PO daily in 6 patients and 80 mg PO daily in 1 patient. The dose was reduced in all but 1 patient due to side effects. The ocular tumors were controlled in all patients with an average follow-up of 13 months (range 4–24 months). Literature review identified 7 manuscripts that described belzutifan-mediated control of ocular tumors in patients with VHL-associated RHs in 21 patients.
Conclusion
The drug belzutifan shows great promise for controlling RHs and preventing vision loss in patients with VHL. Further work needs to address the optimal dose, role of the drug as a neoadjuvant therapy, and long-term efficacy and tolerability of the drug in a larger cohort of patients with ocular tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.
- Institute for Vision Research, University of Iowa, Iowa City, IA, USA.
- Department of Pediatrics, University of Iowa, Iowa City, IA, USA.
- Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Zitieren
APA
Jamshidi, F., Lozano, L., Tucker, B., Andorf, J., Sohn, E., Stone, E., Groves, A., Zakharia, Y., Boldt, H. C., & Binkley, E. (2024). Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Ocular Oncology and Pathology, 10(3), 154-161. https://doi.org/10.1159/000539434
Vancouver
Jamshidi F, Lozano L, Tucker B, Andorf J, Sohn E, Stone E, et al. Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Ocular Oncology and Pathology. 2024;10(3):154-161. doi:10.1159/000539434
BibTeX
@article{Jamshidi2024,
author = {Jamshidi, Farzad and Lozano, Lola and Tucker, Budd and Andorf, Jean and Sohn, Elliott and Stone, Edwin and Groves, Andrew and Zakharia, Yousef and Boldt, H Culver and Binkley, Elaine},
title = {Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature},
journal = {Ocular Oncology and Pathology},
year = {2024},
volume = {10},
number = {3},
pages = {154--161},
doi = {10.1159/000539434}
}
EUVIMED